Streetbeat News

Stock Prices

NKE

Amy Raskin, on CNBC, has announced that her firm has trimmed its position in Nike, Inc. (NKE).

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:08 pm

UBER

On CNBC, Sarat Sethi revealed that he has reduced his investment in Uber Technologies, Inc. This could indicate a lack of confidence or a strategic portfolio adjustment.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:07 pm

CSCO

On CNBC, Sarat Sethi revealed that he has sold his position in Cisco Systems, Inc. This announcement could influence investor sentiment and potentially impact Cisco's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:06 pm

KYMR

Kymera Therapeutics shares have seen an uptick following the announcement of their objectives for the year 2024. The company's forward-looking goals have likely instilled confidence among investors, contributing to the positive movement in stock price.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:05 pm

PFE

On CNBC, Josh Brown, a well-known financial analyst, announced that he has purchased shares of Pfizer, Inc. (PFE).

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:04 pm

DIS

SONY

Zee Entertainment Enterprises Ltd. missed a $200 million payment to Walt Disney Co's India unit for cricket TV rights, amid financial challenges and uncertainty over its merger with Sony Group Corp. The missed payment raises concerns about Zee's cash conservation and potential legal issues, while Disney seeks explanations. Zee's stock struggles as it relies on cricket rights to boost viewership and advertising in cricket-loving India. Disney's stock dipped 1.08% to $90.56.

Portfolio Pulse from Shivani Kumaresan

January 09, 2024 | 5:02 pm

DTIL

TGTX

Precision BioSciences' stock is up following the announcement of a licensing agreement with TG Therapeutics for the development of Azer-Cel, a treatment for autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:01 pm

AXNX

Five analysts have provided ratings on Axonics (NASDAQ:AXNX) with diverse perspectives ranging from bullish to bearish. Over the last three months, there have been 2 bullish and 3 somewhat bullish ratings, with no changes in the past 30 days. The average 12-month price target is $70.0, with a high of $75.00 and a low of $63.00, marking a decrease from the previous average of $75.25. Analysts from Truist Securities, Piper Sandler, Morgan Stanley, Needham, and Leerink Partners have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Axonics, a medical technology company, has shown a revenue growth of 32.27% as of September 30, 2023, and has a market capitalization below the industry average. It also boasts a net margin of 4.22%, ROE of 0.65%, ROA of 0.6%, and a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 5:01 pm

LCII

LCI Indus (NYSE:LCII) has been evaluated by 4 analysts in the past three months, with mixed opinions. The average 12-month price target is now $125.00, down from $130.00, with a high estimate of $140.00 and a low of $105.00. LCI Industries supplies components for OEMs in various industries, but its financial health shows challenges with a revenue decline of -15.26%, below-average net margin, ROE, and ROA, although it has a sound debt-to-equity ratio. Analysts' ratings and price targets reflect their views on the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 5:00 pm

ENTG

Keybanc has reaffirmed its Overweight rating on Entegris (NASDAQ:ENTG) and increased its price target from $107.00 to $136.00. Entegris' shares are currently trading at $112.87, and the new price target suggests a potential upside of 20.49%. Entegris is a supplier of materials and solutions for the semiconductor and high-technology industries.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 5:00 pm